Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 41.59% is 313% above its 5-year average of 10.08%, near the high end of its 5-year range (-54.78%–41.59%).
As of the fiscal period ended Tuesday, June 30, 2026. 17.13% above its 12-month average of 35.51%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
RETURN ON EQUITY (ROE)
41.59%
RETURN ON EQUITY (ROE) AVG TTM
35.51%
RETURN ON EQUITY (ROE) AVG 3Y
8.97%
RETURN ON EQUITY (ROE) AVG 5Y
10.08%
RETURN ON EQUITY (ROE) AVG 10Y
15.55%
RETURN ON EQUITY (ROE) AVG 15Y
18.33%
RETURN ON EQUITY (ROE) AVG 20Y
21.14%
CURRENT VS TTM AVG
+17.13%
CURRENT VS 3Y AVG
+363.68%
CURRENT VS 5Y AVG
+312.72%
CURRENT VS 10Y AVG
+167.53%
CURRENT VS 15Y AVG
+126.86%
CURRENT VS 20Y AVG
+96.70%
SECTOR MEDIAN · HEALTHCARE
13.25%
median of 83 covered companies
CURRENT VS SECTOR MEDIAN
+213.87%
vs the sector median at left
Bristol-Myers Squibb Company
Market Cap
$132.14B
Return on Equity (ROE)
41.59%
TTM Avg
35.51%
3Y Avg
8.97%
5Y Avg
10.08%
Market Cap
$134.24B
Return on Equity (ROE)
21.76%
TTM Avg
8.96%
3Y Avg
15.60%
5Y Avg
19.47%
Market Cap
$123.70B
Return on Equity (ROE)
17.28%
TTM Avg
15.07%
3Y Avg
13.91%
5Y Avg
13.46%
Market Cap
$122.58B
Return on Equity (ROE)
6.16%
TTM Avg
4.23%
3Y Avg
6.35%
5Y Avg
7.74%
Market Cap
$144.25B
Return on Equity (ROE)
7.61%
TTM Avg
7.38%
3Y Avg
9.51%
5Y Avg
10.24%
Market Cap
$105.97B
Return on Equity (ROE)
15.55%
TTM Avg
14.50%
3Y Avg
15.05%
5Y Avg
14.30%
Market Cap
$158.39B
Return on Equity (ROE)
5.09%
TTM Avg
9.04%
3Y Avg
13.32%
5Y Avg
16.07%
Market Cap
$104.10B
Return on Equity (ROE)
N/A
TTM Avg
-189.06%
3Y Avg
-180.53%
5Y Avg
3473.86%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bristol-Myers Squibb Company (BMY) | $132.14B | 41.59% | 35.51% | 8.97% | 10.08% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $134.24B | 21.76% | 8.96% | 15.60% | 19.47% |
| Intuitive Surgical, Inc. (ISRG)vs › | $123.70B | 17.28% | 15.07% | 13.91% | 13.46% |
| CVS Health Corp. (CVS)vs › | $122.58B | 6.16% | 4.23% | 6.35% | 7.74% |
| Danaher Corporation (DHR)vs › | $144.25B | 7.61% | 7.38% | 9.51% | 10.24% |
| Medtronic plc (MDT)vs › | $118.26B | N/A | 9.71% | 8.51% | 8.44% |
| Stryker Corporation (SYK)vs › | $105.97B | 15.55% | 14.50% | 15.05% | 14.30% |
| Pfizer Inc. (PFE)vs › | $158.39B | 5.09% | 9.04% | 13.32% | 16.07% |
| McKesson Corporation (MCK)vs › | $104.10B | N/A | -189.06% | -180.53% | 3473.86% |
| Sanofi (SNY)vs › | $103.62B | 5.82% | 9.06% | 9.15% | 10.86% |
ROE
41.6%
ROA
10.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 41.59% |
| 2026-03-31 | 36.25% |
| 2025-12-31 | 38.19% |
| 2025-09-30 | 32.55% |
| 2025-06-30 | 28.96% |
| 2025-03-31 | 31.16% |
| 2024-12-31 | -54.78% |
| 2024-09-30 | -42.34% |
| 2024-06-30 | -38.44% |
| 2024-03-31 | -37.28% |
| 2023-12-31 | 27.27% |
| 2023-09-30 | 28.57% |
| 2023-06-30 | 24.91% |
| 2023-03-31 | 22.97% |
| 2022-12-31 | 20.37% |
| 2022-09-30 | 20.44% |
| 2022-06-30 | 20.30% |
| 2022-03-31 | 19.79% |
| 2021-12-31 | 19.46% |
| 2021-09-30 | -14.52% |
| 2021-06-30 | -13.80% |
| 2021-03-31 | -16.54% |
| 2020-12-31 | -23.84% |
| 2020-09-30 | -0.09% |
| 2020-06-30 | -1.15% |
| 2020-03-31 | 1.91% |
| 2019-12-31 | 6.66% |
| 2019-09-30 | 32.04% |
| 2019-06-30 | 38.65% |
| 2019-03-31 | 33.80% |
| 2018-12-31 | 35.07% |
| 2018-09-30 | 10.50% |
| 2018-06-30 | 3.05% |
| 2018-03-31 | 7.18% |
| 2017-12-31 | 8.58% |
| 2017-09-30 | 28.61% |
| 2017-06-30 | 31.20% |
| 2017-03-31 | 33.55% |
| 2016-12-31 | 27.55% |
| 2016-09-30 | 21.56% |
| 2016-06-30 | 19.24% |
| 2016-03-31 | 10.94% |
| 2015-12-31 | 10.97% |
| 2015-09-30 | 11.77% |
| 2015-06-30 | 11.84% |
| 2015-03-31 | 14.49% |
| 2014-12-31 | 13.49% |
| 2014-09-30 | 17.94% |
| 2014-06-30 | 17.54% |
| 2014-03-31 | 18.68% |
| 2013-12-31 | 16.91% |
| 2013-09-30 | 18.76% |
| 2013-06-30 | 9.46% |
| 2013-03-31 | 10.75% |
| 2012-12-31 | 14.39% |
| 2012-09-30 | 13.58% |
| 2012-06-30 | 22.16% |
| 2012-03-31 | 23.41% |
| 2011-12-31 | 23.25% |
| 2011-09-30 | 20.15% |
| 2011-06-30 | 20.30% |
| 2011-03-31 | 20.91% |
| 2010-12-31 | 19.74% |
| 2010-09-30 | 66.65% |
| 2010-06-30 | 68.04% |
| 2010-03-31 | 70.28% |
| 2009-12-31 | 71.49% |
| 2009-09-30 | 26.39% |
| 2009-06-30 | 38.61% |
| 2009-03-31 | 39.17% |
| 2008-12-31 | 42.86% |
| 2008-09-30 | 30.25% |
| 2008-06-30 | 20.36% |
| 2008-03-31 | 20.23% |
| 2007-12-31 | 20.50% |
| 2007-09-30 | 19.01% |
| 2007-06-30 | 14.87% |
| 2007-03-31 | 15.21% |
| 2006-12-31 | 15.86% |
| 2006-09-30 | 19.14% |
| 2006-06-30 | 24.28% |
| 2006-03-31 | 27.53% |
| 2005-12-31 | 26.77% |
| 2005-09-30 | 23.43% |
| 2005-06-30 | 22.53% |
| 2005-03-31 | 18.85% |
| 2004-12-31 | 23.41% |
| 2004-09-30 | 26.56% |
| 2004-06-30 | 28.57% |
| 2004-03-31 | 31.85% |
| 2003-12-31 | 32.21% |
| 2003-09-30 | 29.24% |
| 2003-06-30 | 24.90% |
